Trinity Biotech reported Q3 2024 revenue of $15.2 million, up 3.2% year-over-year, driven by a 60.1% increase in Point-of-Care sales to $4.3 million. Operating loss narrowed to $2.6 million from $4.5 million in Q3 2023, reflecting higher gross margins and reduced overheads. The company reiterated guidance to achieve $20 million annualized run-rate EBITDASO on $75 million annualized revenues by Q2 2025.TrinScreen HIV sales reached $2.4 million as demand remained strong. Clinical laboratory revenue declined 9.6% to $10.8 million, with growth in clinical chemistry offset by lower haemoglobin sales. Gross margin held steady at 35.0% excluding one-time charges. R&D expenses decreased to $1.0 million, while SG&A expenses fell $1.2 million to $6.5 million on cost-saving initiatives.The company is progressing on its restructuring plan, including offshoring corporate services and consolidating manufacturing. It also completed two diagnostic technology acquisitions in oncology and maternal health. Trinity Biotech ended the quarter with $2.8 million in cash and raised $7.1 million through an at-the-market equity offering program.

Trinity Biotech reported Q3 2024 revenue of $15.2 million, up 3.2% year-over-year, driven by a 60.1% increase in Point-of-Care sales to $4.3 million. Operating loss narrowed to $2.6 million from $4.5 million in Q3 2023, reflecting higher gross margins and reduced overheads. The company reiterated guidance to achieve $20 million annualized run-rate EBITDASO on $75 million annualized revenues by Q2 2025.TrinScreen HIV sales reached $2.4 million as demand remained strong. Clinical laboratory revenue declined 9.6% to $10.8 million, with growth in clinical chemistry offset by lower haemoglobin sales. Gross margin held steady at 35.0% excluding one-time charges. R&D expenses decreased to $1.0 million, while SG&A expenses fell $1.2 million to $6.5 million on cost-saving initiatives.The company is progressing on its restructuring plan, including offshoring corporate services and consolidating manufacturing. It also completed two diagnostic technology acquisitions in oncology and maternal health. Trinity Biotech ended the quarter with $2.8 million in cash and raised $7.1 million through an at-the-market equity offering program.